As­traZeneca wins a round in their PhI­II COPD bout with GSK — but can they catch up?

Mene Pan­ga­los

As­traZeneca gets to build its case for their triple com­bo for COPD as reg­u­la­tors on both sides of the At­lantic give it a care­ful re­view. And that could trig­ger some added fret­ting at GSK, which has been look­ing to se­cure a beach­head on the COPD mar­ket with their own triple — Trel­e­gy El­lip­ta.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER